JT Merrill

1.2k total citations
26 papers, 664 citations indexed

About

JT Merrill is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, JT Merrill has authored 26 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Rheumatology, 9 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Immunology. Recurrent topics in JT Merrill's work include Systemic Lupus Erythematosus Research (19 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cytokine Signaling Pathways and Interactions (4 papers). JT Merrill is often cited by papers focused on Systemic Lupus Erythematosus Research (19 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cytokine Signaling Pathways and Interactions (4 papers). JT Merrill collaborates with scholars based in United States, United Kingdom and Germany. JT Merrill's co-authors include R G Lahita, Jill P. Buyon, Caroline Gordon, Paul Brunetta, Kyriakos A. Kirou, M. Pétri, C. Le, S.M. Berney, James Ja and Wendy I. White and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

JT Merrill

25 papers receiving 649 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
JT Merrill United States 9 494 383 191 66 55 26 664
Fu-lin Tang China 15 423 0.9× 385 1.0× 89 0.5× 97 1.5× 14 0.3× 52 860
Bernie Scallon Sweden 5 200 0.4× 234 0.6× 103 0.5× 63 1.0× 27 0.5× 6 639
Emma Ross United Kingdom 7 293 0.6× 272 0.7× 96 0.5× 108 1.6× 161 2.9× 8 729
Vicente Baca Mexico 14 343 0.7× 321 0.8× 53 0.3× 78 1.2× 15 0.3× 21 681
Norifumi Sawamukai Japan 14 359 0.7× 267 0.7× 65 0.3× 72 1.1× 10 0.2× 25 672
Yonsu Son Japan 16 412 0.8× 264 0.7× 37 0.2× 55 0.8× 13 0.2× 49 712
D. van Schaardenburg Netherlands 9 628 1.3× 178 0.5× 209 1.1× 50 0.8× 6 0.1× 34 747
Nien Yee Kow Singapore 7 489 1.0× 411 1.1× 85 0.4× 69 1.0× 6 0.1× 10 675
Wendy Douglass United Kingdom 9 246 0.5× 166 0.4× 88 0.5× 30 0.5× 9 0.2× 12 493
L De Rycke Belgium 8 469 0.9× 162 0.4× 215 1.1× 55 0.8× 4 0.1× 15 610

Countries citing papers authored by JT Merrill

Since Specialization
Citations

This map shows the geographic impact of JT Merrill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JT Merrill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JT Merrill more than expected).

Fields of papers citing papers by JT Merrill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JT Merrill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JT Merrill. The network helps show where JT Merrill may publish in the future.

Co-authorship network of co-authors of JT Merrill

This figure shows the co-authorship network connecting the top 25 collaborators of JT Merrill. A scholar is included among the top collaborators of JT Merrill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JT Merrill. JT Merrill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Merrill, JT, Nikolay Delev, Sreeparna Banerjee, et al.. (2022). PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design. SHILAP Revista de lepidopterología. A100–A101. 2 indexed citations
2.
3.
4.
Amoura, Zahir, et al.. (2017). OP0234 Clinical and biologic effects of icosl blockade by amg 557 in subjects with lupus arthritis. Annals of the Rheumatic Diseases. 76. 151–152. 1 indexed citations
5.
6.
Merrill, JT, DJ Wallace, Stephen Wax, et al.. (2017). 8 Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomisedrandomized, placebo-controlled, phase iib study. INFM-OAR (INFN Catania). A4–A6. 2 indexed citations
7.
Wallace, DJ, EM Ginzler, JT Merrill, et al.. (2017). OP0232 Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE. Annals of the Rheumatic Diseases. 76. 150–151. 5 indexed citations
8.
Wallace, DJ, et al.. (2017). SAT0236 Safety and disease activity changes in an extension of a phase IIB study of atacicept in patients with SLE (address II). Annals of the Rheumatic Diseases. 76. 863–863. 1 indexed citations
9.
Bandyopadhyay, Soham, Seán Connolly, Omar Jabado, et al.. (2016). De-Convolution of Whole Blood Transcriptomic Data From a Phase Jib, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus. Clinical and Experimental Rheumatology. 34(4). 2463–2464. 1 indexed citations
10.
Buyon, Jill P., Marta Guerra, Dong Zhang, et al.. (2016). Angiogenic Factor Imbalance Early in Pregnancy Predicts Adverse Outcomes in Patients With Lupus and Antiphospholipid Antibodies: Results of the PROMISSE Study. Obstetric Anesthesia Digest. 36(4). 213–214. 5 indexed citations
11.
Connolly, Seán, Omar Jabado, S. Kelly, et al.. (2015). De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus. Queensland's institutional digital repository (The University of Queensland). 67. 1 indexed citations
12.
Merrill, JT, Marta E. Alarcón‐Riquelme, Michelle Petri, et al.. (2015). OP0079 Pharmacodynamic Changes in Gene Expression Observed in Two Phase 3 Trials of Baff Blockade with Tabalumab in SLE. Annals of the Rheumatic Diseases. 74. 98–99. 1 indexed citations
13.
Hill, Andrew A., Fred Immermann, Padmalatha S. Reddy, et al.. (2013). FRI0003 Determination of interferon (IFN) signatures for sle patients may be critical for optimal treatment selection but depends on the genes chosen: report from the bold (biomarkers of lupus disease) study. Annals of the Rheumatic Diseases. 72. A369–A370. 2 indexed citations
14.
Petri, Michelle, Caroline Gordon, JT Merrill, et al.. (2011). Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Carolina Digital Repository (University of North Carolina at Chapel Hill). 1 indexed citations
15.
Merrill, JT, M. Pétri, Kyriakos A. Kirou, et al.. (2011). Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Annals of the Rheumatic Diseases. 70(11). 1905–1913. 191 indexed citations
16.
Merrill, JT, et al.. (2011). Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 20(7). 709–716. 103 indexed citations
17.
Merrill, JT, Rubén Burgos‐Vargas, René Westhovens, et al.. (2008). The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study. Queensland's institutional digital repository (The University of Queensland). 58(12). 4031–4032. 15 indexed citations
18.
Olech, Ewa & JT Merrill. (2005). DHEA supplementation: the claims in perspective.. Cleveland Clinic Journal of Medicine. 72(11). 965–966. 16 indexed citations
19.
Merrill, JT & R G Lahita. (2000). Sex hormone binding globulins and atherosclerotic risk in systemic lupus. Lupus. 9(3). 217–222. 3 indexed citations
20.
Roubey, Robert, JT Merrill, Felecia S. Walton, et al.. (1991). Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18). The Journal of Immunology. 146(10). 3557–3562. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fu-lin Tang Breakdown of academic impact, for papers by Bernie Scallon Breakdown of academic impact, for papers by Emma Ross Breakdown of academic impact, for papers by Vicente Baca Breakdown of academic impact, for papers by Norifumi Sawamukai Breakdown of academic impact, for papers by Yonsu Son Breakdown of academic impact, for papers by D. van Schaardenburg Breakdown of academic impact, for papers by Nien Yee Kow Breakdown of academic impact, for papers by Wendy Douglass Breakdown of academic impact, for papers by L De Rycke
Rankless by CCL
2026